Abstract | Cancer incidence increases with advanced age. The Cancer and Aging Research Group, in partnership with the National Institute on Aging and NCI, have summarized the gaps in knowledge in geriatric oncology and made recommendations to close these gaps. One recommendation was that the comprehensive geriatric assessment (CGA) should be incorporated within geriatric oncology research. Information from the CGA can be used to stratify patients into risk categories to better predict their tolerance of cancer treatment, and to follow functional consequences from treatment. Other recommendations were to design trials for older adults with study end points that address the needs of the older and/or vulnerable adult with cancer and to build a better infrastructure to accommodate the needs of older adults to improve their representation in trials. We use a case-based approach to highlight gaps in knowledge regarding the care of older adults with cancer, discuss our current state of knowledge of best practice patterns, and identify opportunities for research in geriatric oncology. More evidence regarding the treatment of older patients with cancer is urgently needed.
Introduction
Cancer is a disease of ageing; approximately 60% of all cancers and 70% of cancer mortality occur in persons aged 65 years and older. 1 The number of cancer patients over the age of 65 is projected to increase significantly over the next 20 years. 2 Ageing is a highly individualized process, characterized by physiological and psychosocial changes that can affect tumour biology, decision-making for cancer treatment, tolerance to treatment, and ultimately patient outcomes. Furthermore, there is consi derable heterogeneity in physiological changes that occur with ageing. Historically, clinical trial enrollment of older adults has not reflected the more general population of older patients with cancer. This situation is primarily due to the low overall number of older patients enrolled and overly strict inclusion criteria leading to the enrollment of primarily healthy, 'fit' older adults. 3 It is very difficult to extrapolate clinical trial data to inform treatment decisions of older patients with cancer who are more vulnerable to adverse outcomes because of underlying health issues. 4, 5 The underlying health status of older (aged 65 and above) individuals included within clinical trials is not well characterized, and the results of studies evaluating the efficacy and tolerance of cancer treatment in older patients often conflict. 6 Some researchers have suggested there is no significant relationship between the age of the patient and treatment decisions, delivered dose, toxi city, or clearance rate of drugs, despite age-related physiological changes. 7 Others suggest consideration of several variables in the decision process, such as anticipated remaining life expectancy, the number and severity of comorbid conditions and assessment of the benefits versus the risks of treatment using a compre hensive assessment of health status. 8 Most clinicians agree that age alone should not be used as a rationale to deny chemo therapy to older patients. 9 The available evidence suggests that poor health status and functional limitations, comorbidity, cognitive decline, and/or limited social support correlate with toxi city to therapy and cancer outcomes. 10 Although the commonly used Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) performance status measures do correlate with treatment toxicity, these tools alone do not reliably predict toxic effects in the older adult. 11, 12 Comprehensive Geriatric Assessment (CGA), a compilation of standardized tools to assess geriatric domains such as comorbidity, functional status, nutrition, physical function, cognitive perfor mance, and social support, can help define the 'stage of the ageing. ' [13] [14] [15] [16] CGA can better quantify remaining life expectancy, predict tolerance to treatment 14, 17, 18 and add important information to the traditional perfor mance status assessment tools, such as KPS or ECOG, used in oncology. 19 Unfortunately, clinical trial data that dictate evidencebased care for older patients with cancer have not generally included geriatric assessment tools. 9, 10 The significant gaps in knowledge related to cancer treatment in older and/or vulnerable adults led to the formation of the Cancer and Aging Research Group (CARG), 20 a coalition of investigators dedicated to linking geriatric oncology researchers together to work towards a common goal of improving clinical care for
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older adults. CARG held a conference in collabor ation with the National Institute of Aging (NIA) and the National Cancer Institute (NCI). 10 In this Review, we use a case-based approach to highlight important gaps in our knowledge related to the clinical care of older adults with cancer, review recent progress and evidence from the literature that start to close the knowledge gaps, and indicate how one might begin to incorporate these practices into clinical care.
Moving beyond chronological age
Case 1 SM is a 78-year-old woman with hypertension, arthritis, and diabetes. She lives alone, but receives help from her daughter who lives nearby. She takes six different medications per day and occasionally is forgetful in taking them. Her daughter assists her with taking her medications by maintaining her pillbox. SM has limitations in walking one block, primarily because of increased 'joint aches' and she has fallen once in the past 6 months but did not seek medical advice at the time of the fall. She has been losing weight (15 lbs), which she attributes to a decrease in her social activities (her usual evening meal at the corner diner). On physical examination, her primary physician palpated a breast mass that was biopsied and revealed an infiltrating ductal carcinoma, which was triple negative (that is, negative for expression of the oestrogen receptor, progesterone receptor and HER2 receptor). Blood assessment revealed her alkaline phosphatase level was elevated to double the upper value in the normal range, although other liver function tests were normal. Her creatinine value was 1.3 mg/dl (creatinine clearance is 30 ml/min). A bone radionuclide scan revealed findings suspicious of metastatic disease, which was confirmed at needle biopsy. Abdominal CT revealed metastatic disease to the liver. She presents today to discuss treatment options.
Discussion of case 1
There are several reasons why it can be challenging to apply the results of cancer clinical trials into the treatment of older adults with cancer in the community. Several studies have demonstrated that the mean age of patients enrolled on cancer clinical trials is lower than the mean age of patients with the disease. 21 For example, an evaluation of 133 phase I studies of 33 drugs in patients from Japan and the USA showed the median age of patients enrolled was 58 years, which was lower than the median age of patients in the Japanese and the USA cancer populations (approximately 70 years). 22 There is considerable biological and physiological heterogeneity and complexity in older adults, 10 and this complexity is not typically addressed within our current clinical trials system. Underlying health status assessment and geri atric domains are predictive of future morbidity and morta lity in community-dwelling adults aged 65 and over, and they could affect cancer treatment tolerance and outcomes. 11, 14, 23 In a large, nationally representative database, it was found that functional problems and vulnerability due to adverse age-associated characteristics were more common in patients with cancer than in age-matched patients without cancer (Figure 1 ). 24 Underlying health issues and deficits in geriatric domains lead to signi ficant heterogeneity in remaining life expectancy for older adults, and an accurate estimation of life expectancy is important for making appropriate and relevant treatment decisions for patients with cancer. Several studies have demonstrated that older adults enrolled on clinical trials are at an increased risk for treatment-related toxicity, 10, 25 suggesting that factors other than increased age may place many older adults at heightened risk for adverse outcomes.
11
To bridge this knowledge gap, a more-detailed assessment of the baseline characteristics of older adults enrolled in clinical trials is needed. As a minimum, this assessment or CGA would include evaluating the individual's functional status, comorbid medical conditions, psychological state, social support, nutritional status, and cognitive state ( Table 1) . 26 Based on studies of non-cancer patients, each domain of a CGA is an independent predictor of morbidity and mortality in older adults. 17 In addition to including these measures as part of the baseline evaluation, longitudinal inclusion of a CGA at standard time points would further our understanding of the impact of both the cancer and its treatment on these geriatric outcomes.
The impact of therapy on function and cognition can be defining factors influencing the patient's preference for receiving treatment, 27 as well as identifying the need for additional family support or community resources to assist the patient through the treatment course. Cancer clinical trial end points typically focus on disease-free survival and overall survival; however, additional end points may better guide the risks and benefits of therapy in an older adult, such as the impact of therapy on function and cognition. 10, 28 For example, the FOCUS-2 trial that evaluated chemotherapy for older and/or frail adults with colorectal cancer evaluated a composite end point of toxicity and perceived benefit by the patient in addition to stan dard response criteria. 29 This study used a 2 × 2 factori al design to randomly assign 'frail' (that is, considered unfit for full-dose combination chemotherapy by their physician) older adults with metastatic colorectal cancer to one of four first-line systemic therapies using an attenuated starting dose (80% of the standard dose). In total, 459 patients Key points ■ The available evidence suggests that functional limitations, comorbidity, cognitive decline, and/or limited social support correlate with toxicity to therapy and cancer outcomes in patients aged 65 and over ■ Information from the comprehensive geriatric assessment can be used to stratify patients into risk categories to better predict their tolerance to treatment and follow functional consequences from treatment ■ Although fit, older adults do as well as their younger counterparts when receiving treatment within clinical trials, older adults are at increased risk for treatmentrelated toxic effects ■ The proportion of older adults in trials should include those with underlying health status characteristics that better reflect the age and health status of patients seen in the community ■ The focus for treatment within oncology clinical research to be 'more aggressive ' continues to accentuate the current under-representation of older adults ■ When caring for older cancer patients in oncology offices, the necessary additional time should be provided to perform assessments and to monitor and manage toxicities
were assigned to one of the following arms: 48-h intravenous 5-fluorouracil (5-FU); oxaliplatin plus 5-FU; capecitabine; or oxaliplatin plus capecitabine. In addition to a standard quality-of-life questionnaire, a composite outcome of overall treatment utility was incorporated in an attempt to capture patient and physician satis faction with the outcome of each treatment decision. The median patient age was 74 years with 13% of participants over the age of 80 years. The primary reason patients were considered 'unfit' for standard therapy was older chronological age. There was a trend towards benefit with use of oxaliplatin, in this attenuated dosing schedule, although the primary outcome was not statistically significant (median progression-free survival, 5.8 months versus 4.5 months, P = 0.07). No significant increase in grade 3 toxic effects was seen with the use of oxaliplatin and its use was associated with increased overall treatment utility, suggesting a palliative benefit. Alternatively, although capecitabine was equivalent in efficacy to 5-FU, there was no benefit in quality of life and there was also a significantly higher proportion of grade 3 or higher toxi city in the capecitabine arm compared with 5-FU (40% versus 30%, P = 0.03). This study provides evidence for treatment of 'non-fit' older adults with metastatic colo rectal cancer with an attenuated chemotherapy regimen and introduces additional outcome measures to help quantify the palliative benefit a patient may receive from therapy. 29 This approach provided meaningful information for the clinician beyond the standard cancer end points regarding treatment in a frail older adult with colorectal cancer.
Another routine part of clinical trials is to evaluate the toxicity of the cancer therapy as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE).
11,12 Grade 3 (severe or medically significant), grade 4 (life threatening), or grade 5 (treatment-related mortality) toxicities are typically captured and reported in clinical trials and are considered to be 'dose limiting' . However, several grade 2 toxic effects may also be of importance to older adults with cancer. These toxi cities are defined as moderate toxicities that may limit the patient's ability to complete instrumental activities of daily living, such as preparing meals or shopping for groceries. Ageassociated changes in physiology may impact the ability of an older adult to withstand grade 1 or 2 toxicity. For example, grade 2 diarrhoea (increase of four to six stools above baseline) might have significant consequences in an older adult, since ageing is associated with an increased vulnerability to experience gastro intestinal side effects and fluid depletion. 7 Grade 2 peripheral neuropathy may significantly affect performance status or increase the risk of falls in a vulnerable older patient. Furthermore, the longitudinal impact of lower grade toxicities (that is, grades 1 and 2) is frequently not reported. This leads to an unanswered question of whether grade 3-5 toxicities are preceded by lower grade toxicities, which could serve as a warning sign to modify the drug dosing.
Predictive risk-stratification schemes allow clinicians to identify which patients are at highest risk for chemotherapy toxicity. Two recent studies rigorously evaluated the role of CGA for predicting toxicity from chemo therapy.
In a study of 500 patients aged 65 and over perfor med by CARG, CGA variables were associated with having at least one grade 3-5 toxicity.
11 Both haematological and non-haematological toxicities were captured. Risk factors for grade 3-5 toxicity included: age ≥72 years, cancer type (gastrointestinal or genitourinary), standard dose, poly-chemotherapy, falls in the past 6 months, assistance with instrumental activities of daily living, and decreased social activity. A risk-stratification schema (number of risk factors: % incidence of grade 3-5 toxicity) which scored patients from 0-23 was developed based on the predictive value of each factor for toxicity in a regression analysis. Over 80% of patients who scored 12 or more on the tool developed grade 3-5 toxicity. By contrast, the commonly used KPS scale was not able to identify which older adults were at increased risk. A second study, led by Extermann, developed the Chemotherapy Risk Assessment Scale for High-age patients (CRASH) score in over 500 patients aged 70 years and over. 12 The best model for haematological toxicity included Instrumental Activity of Daily Living (IADL) score, LDH level, diastolic blood pressure, and chemotherapy intensity. The best predictive model for non-haematological toxicity included ECOG performance status, Mini-Mental State score, Mini-Nutritional Score, and chemotherapy intensity. Information from two-thirds of the patients was used to develop the risk stratification scheme, and the tool was validated both in the remaining one-third of patients and in an external cohort.
As described above, CGA variables can help identify older adults at increased risk of chemotherapy-induced toxicity. In community-dwelling older adults, CGA can help estimate remaining life expectancy, and measures within CGA have been shown to be associated with survival in older patients with advanced-stage cancer. 30, 31 Knowledge is growing on how CGA can be best incorporated within geriatric oncology research and for clinical decision making. One conceptual model is that of 'staging the ageing,' which would stratify an older 24 REVIEWS patient's physiology capacity according to their underlying health status. 13 Common terminology used include 'fit, ' which represents no significant CGA deficits versus 'vulnerable, ' which captures mild CGA deficits and 'frail, ' which captures significant CGA deficits such as severe comorbid ity, activity of daily living deficit, or a clinically signifi cant geriatric syndrome (such as dementia or falls). 24 Vulnerability and frailty represent patients who are along a continuum of increased risk for morbidity and mortality. Incorporation of these tools and conceptual framework into clinical research, and potentially clinical care, can help identify which older patients are the most likely to tolerate and benefit from treatment. CGA can also help monitor ageing-associated effects of treatment on outcomes that are especially important to older patients, such as function and cognition. These tools can be used in future research to identify and test interventions to reduce the development of chemo therapy toxicity in vulnerable older populations. Although not clinically applicable at this time, future research could also help identify biomarkers (such as inflammatory markers, telomere changes, genetic corre lates of ageing) [32] [33] [34] that could help supplement the predictive value of clinical measures such as CGA.
Back to the case SM has a recent diagnosis of metastatic breast cancer that is 'triple negative' . Based on the CARG chemotherapy toxicity model for older adults, 11 the following findings of SM from the CGA identified risk factors for chemotherapy toxicity: limitations in walking one block, physical health had decreased her level of social activity, she had a history of falls, and she needed assistance with taking medications. Additional risk factors for chemotherapy toxicity include: decreased creatinine clearance and age greater than 72 years. Based on these risk factors, this patient is at increased risk of chemotherapy toxicity (score of 12; >80% chance of grade 3-5 toxicity). Also, based on the CRASH score SM is at increased risk of haemato logical toxicity if she received chemotherapy, based on her need for assistance with instrumental activities of daily living, which is known to be predictive of chemotherapy toxicity. SM lives alone and has risk factors for falls and these issues should be addressed with interventions to boost caregiver and/or social support prior to initiation of treatment. Several interventions could be considered including: using chemotherapy that is metabolized by the liver (rather than metabolized by the kidney) because she has a decreased creatinine clearance, optimizing her social support, a nutritional consultation, consideration of Meals on Wheels, visiting nurse services to monitor her for toxicity, home safety evaluation with medical alert system for fall risk, and/or rehabilitation to improve functional status.
Improving therapy safety and efficacy
Case 2 MJ is a 75-year-old man with coronary artery disease (he had a post coronary artery bypass graft 2 years ago), hypertension, hyperlipidaemia, and osteoarthritis. Medications include aspirin, atenolol, and lovastatin. Laboratory exam showed mild microcytic anaemia. Laboratory tests also revealed mild renal insufficiency with a creatinine level of 1.2 mg/dl and a glomerular filtration rate of 50 ml/min. Carcinoembryonic antigen level was normal. CT scans revealed a mass in the descen ding colon. The patient underwent hemicolectomy. Pathological examination revealed a stage IIIC (T3, N2) tumour. Geriatric assessment revealed that the patient required assistance with activity of daily living, had frequent falls, and a memory disorder. He is not very active and rests about 50% of the day. Age-related physiological changes may increase the risk of chemotherapy toxicity among older adults. 11, 35 Ageing is associated with decreased intestinal absorption, changes in volume of distribution, decreased hepatic metabolism, and impaired renal excretion. Although studies do report differences in outcomes by age, the mechanisms behind these increased risks in toxi city are not well known. A common theme in recommen dations from experts at the 2010 U13 conference arranged by CARG, in partnership with the National Institute on Aging and NCI was that factors known to be associated with an increased risk of toxicity (such as CGA variables and measures of organ [dys]function) should be routinely studied within clinical trials. 10 There remains a significant gap by which data is gathered for cancer therapeutics in older adults. Current oncology clinical trials often exclude patients with medical problems or health conditions other than cancer, often resulting in exclusion of those with even mild organ dysfunction. A study of patients aged 65 years and over who were being considered for phase I studies over a period of 10 years at a single institution found that close to 30% of patients were not enrolled due to protocol ineligibi lity and the majority of ineligibility was due to organ dysfunction. 5 There is also a common exclusion for patients with secondary cancers, even preva lent cancers such as prostate, breast, or colon treated definitively and that are likely cured at the time of trial partici pation. The overall frequency of secondary cancers is highest among those diagnosed with their first cancer at the age of 50-69 years (16.4% by 25 years of follow up), which causes second malignancies to occur commonly in patients aged 65 years and over. 36 Consequently, very few older patients have been included in FDA-registration trials; for example, only 9% of patients enrolled in FDA-registration trials were 75 years or older. 28 Gaps in knowledge ultimately lead to wide variation in patterns of care in treatment initiation for older adults and increased health-care costs. 10 Bridging this gap requires attention on multiple levels. At the conceptual level, closer attention should be paid to developing trials that are applicable to the population as a whole. The propor tion of older adults in trials should include those with underlying health status characteristics that better reflect the population of patients with the specific cancer and health statuses that are routinely seen in the community. At the development stage of research, a multi disciplinary team specifically including representation from geriatrics should evaluate whether or not the concept and protocol will meet these basic requirements. This process does occur in at least one cooperative group, the Alliance, which has an active Cancer and Aging subcommittee. Investigators within this committee have demonstrated that CGA is feasible within the cooperative group setting. 26 In addition, non-age-restricted clinical trials should strive to gather data including those from older patient cohorts. All trials, especially trials studying therapeutics for cancers that occur commonly in older populations, should have a specific target accrual for patients aged 65 years and over. Ideally, analysis of the safety and efficacy of therapeutic agents related to age and health status should be undertaken prior to approval of the agent by the FDA. The safety and efficacy of new agents being tested for cancers common in the elderly should be evaluated within phase II studies that include at least a proportion of older patients that represent the proportion of older patients with the disease in the community. Progress could be facilitated if there was an FDA requirement for studies to include older adults to inform the geriatric usage section of the package inserts.
Although it may be possible to increase data in fit older adults by incorporating less strict exclusion criteria and by requiring a certain proportion of patients entered onto a trial to be older (especially for those cancers that are most common in older patients), it is more difficult to develop and conduct high-quality clinical trials for patients in the oldest age groups (80 years or older), and for those who are vulnerable or frail. For these patients, the important research questions may be different than for those who are younger and/or fitter. An older frail patient treated with FOLFOX (leucovorin, 5-FU and oxaliplatin) in the adjuvant setting, may discontinue therapy early owing to toxicities and, therefore, not achieve a survival benefit. This same patient may be able to complete a thera peutic course of infusional 5-FU alone and achieve a greater benefit with a less-intense regimen. In fact, subset analyses within clinical trials have shown no overall survival benefit of oxaliplatin for patients aged 70 years and over in the adjuvant setting. 37 It is often the case that new clinical trials test a standard approach against a more-aggressive regimen. This research question is not always appropriate for the older, frailer individual where the efficacy and tolerability of the standard approach is highly questionable. The focus for treatment within oncology clinical research to be 'more aggressive' , therefore, continues to accentuate the current under-representation of older adults because the research study design focuses on increasing efficacy (and usually toxicity) rather than seeing if less-toxic regimens can be equally efficacious. Unfortunately, funding for clinical trials in the USA for re-testing the appropriate dosing, efficacy, and toxicity of drugs already on the market in older patients is quite limited. Given the current incentives, without a mandate for this to change from leadership organizations, such as the NIH, co operative groups, or the FDA, it will be difficult to obtain the necessary data.
In vulnerable and frail older adults, the interactions between cancer, cancer treatment, and comorbidities impacts decision making and survivorship. Specific studies of treatment algorithms are needed for patients who would otherwise be considered ineligible or unfit for most current treatment protocols. The CGA could be incorporated within eligibility criteria. For example, trials could be developed for patients who have functional deficits or a specific type, number, or severity of comorbidity. The geriatric oncology research community are actively trying to develop novel clinical trial designs to study therapeutics in older patients. Some of these designs would stratify patients by CGA at the time of enrollment so that patients at different levels of health status receive more appropriate options at randomi zation. Phase III trials that are not elderly speci fic, but strive to enrol a representative proportion of older patients, should consider having the older patients complete CGA prior to randomization so that these factors can be used in the analysis of who is most likely to benefit. CGA has been shown to be feasible in this context within the cooperative group setting.
26 These issues will be addressed during the second U13 conference to be held in November 2012. Trials providing highimpact data should be available for accrual at as many sites as possible, including tertiary care institutions, cancer centres, and community settings. Supplemental financial incentives for enrolling patients onto these trials should be considered to support the necessary infra structure and trials should be available across different cooperative groups. In addition, high quality observational cohort studies that follow patients in the 'real world' community setting with incorporation of CGA tools at defined time points could help bridge gaps in knowledge. An observational cohort study would pros pectively follow over a defined period of time a group of older patients with cancer who have specific features in common. Such studies examine predefined primary outcomes such as safety and efficacy of cancer treatments. Observational cohort studies are different from registries, which collect information on incident events, but do not have prospectively defined outcomes, sample size, or duration of follow up determined at inception. Rigorous observational cohort studies can complement ran domized controlled trial data with information on efficacy, safety, and patient adherence with cancer treatment in a population of real-world patients. 38 Back to the case The patient has several comorbidities including mild renal insufficiency. Geriatric assessment reveals deficits and he should be considered at high risk for toxicity from chemotherapy. His health status is poor. Unfortunately, there are few data to guide the practitioner in weighing the risks and benefits of adjuvant chemotherapy for this patient. On the one hand, his cancer is high risk and has at least a 50% chance of recurrence. On the other hand, he has a high risk of toxicity from chemotherapy and possible adverse effects on function and cognition. At the age of 75 years, in the lowest health status cate gory, his life expectancy if he did not have cancer is estimated to be 5 years. 39 The best regimen for adjuvant treatment, FOLFOX or 5-FU alone or capecitabine, is also contro versial owing to a limited understanding of the risk-benefit ratio of adjuvant therapy in patients aged 75 years and over with poor health status. 37 A clinical trial that evaluated the risks and benefits of adjuvant chemotherapy in older, vulnerable patients that measures not only survival but effects of treatment on function and cognition would help the practitioner and patient determine the best course of action. This case illustrates the significant gaps in knowledge that exist for older patients who are commonly seen in clinical practice as well as the need to further develop geriatric oncology research to gather evidence for these patients.
Improving infrastructure
Case 3 JO is a 75-year-old African American man with diabetes (on insulin treatment), hypertension, atrial fibrillation (on warfarin treatment) and hearing loss who presents with back pain. He is diagnosed with Gleason Score 7, metastatic prostate cancer. He walks with a cane, and had a fall without injury in the past year. His wife has Alzheimer's disease and he is the primary caregiver for her. They live in an apartment in an urban area, with a working daughter who visits at weekends, and who does their shopping and helps organize their medications. He started on androgen-deprivation therapy injections every 3 months plus zoledronic acid infusions for osteoporosis. He missed the first scheduled follow-up appointment to start therapy, is 2 h late to the next one, and he is considered 'noncompliant' with therapy.
Discussion of case 3
Another vital unmet need in geriatric oncology is the lack of clinical and research trial infrastructure that is compatible with the needs of older adults. Specific barriers to treatment for older adults should be identified, and programmes to overcome these barriers need to be developed if we are to treat older adults optimally. These barriers include (but are not limited to) difficulties with transportation to treatment centres, difficulty comple ting their daily activities, the frequent need to serve as a caregiver for an ill or dependent spouse, poor social support, and significant financial barriers, including the cost of medications or caregiver costs. Rarely do onco logy clinic staff have the necessary, specific training and time to handle geriatrics issues. When caring for older patients with cancer in oncology offices, the necessary additional time is not usually provided to complete the consent process, perform relevant geriatric assessments, or to manage the higher likelihood of toxicities expected in this population. 6 Furthermore, additional age-appropriate infrastructure to accomplish these tasks is rarely present to support participation of a trial for frail older adults. It will be difficult to improve trial enrollment without an upgrade in the infrastructure to support the most vulnerable of patients.
Given the above barriers, it is essential to build the necessary infrastructure to provide cancer care for older, frailer adults who comprise the majority of patients with cancer. This is especially true for clinical trial enrollment, where older adults are less likely to be enrolled than their younger counterparts. 21 Improvements in trial enrollment by older adults could potentially result from better tailoring of oncology care to their unique needs. Examples include wider, lower examination tables for patient comfort; easier access to necessary assistive devices, such as wheelchairs; and doorways and hallways to accommodate wheelchairs and geriatric assessment testing such as gait speed assessment. In addition, developing and expanding community-based treatments and trials for older adults would eliminate the need for frail, older adults to travel long distances to participate in clinical trials. Research nurses and data managers should receive specific training in the care of older adults. Data collection from remote locations can also be improved by incorporating advanced technology. Home-monitoring programmes using nurse or social-worker visits, telephone calls, or internet portals to support well being during cancer therapy might be promising, and should be explored further. 40 In addition, more consistent and earlier collabor ation of oncologists with geriatric specialists is essential. A multidisciplinary team that includes providers with specific geriatric training should collaborate closely to design, implement, and execute specifically designed clinical trials for older adults. Integrating geriatricians and other providers with specific geriatric training and experience into an older patient's treatment plan could reap great benefits. For example, it can potentially improve adherence to therapies through careful attention to polypharmacy. It can help minimize the impact of toxi cities, particularly if the patient has functional impairment caused by other comorbid conditions, by providing appropriate support throughout treatment regimens. Targeted assistance based on parti cular comorbidities, such as cardiovascular disease or diabetes, is advised. The inclusion of other health-care providers including clinical psychologists, social workers, physician exten ders, and physical and occupational therapists, especially those with geriatric training, is critical in treating older patients with cancer.
The U13 grant (that is intended to be associated with the aforementioned conference) and dissemi nation of the conference proceedings will hopefully help stimulate novel research ideas that will ultimately allow for the development of evidence-based recommen dations to improve decision making and outcomes of older patients with cancer. Although there is a wealth of information from geriatrics on how to improve outcomes in communitydwelling older adults, more research is needed regarding the impact of these evidence-based recommendations for geriatric oncology patients. An oncologist interested in practical recommendations on improving outcomes for older patients could refer to clinical guidelines and references. 41 Back to the case In treating this vulnerable older man with moderategrade prostate cancer, it is important to balance the need to control his cancer using androgen-deprivation therapy with his advancing frailty, which is likely to be exacerbated by the therapy. 42 In addition, he has a number of social limitations that threaten his independence and prevent him from attending the clinic, including the need to care for his cognitively impaired spouse. Prior to him star ting therapy, every effort should be made to 'prehabilitate' him with physical therapy in the home, provide additional social support to help maintain his independence, a home safety evaluation should be conducted to prevent more falls, and transportation to and from the hospital should be initiated using local hospital or insurance services, cancer society resources, or volun teers. Given his history of falls, he should be assessed for the need for an assistive device, and a wheelchair should be provided during visits to the hospital. He and his family must be educated on the likely exacerbation of his diabetes with the initiation of androgen-deprivation therapy, and the need for careful monitoring of his blood sugars. Provisions must be made for someone to care for his wife when he comes to appointments, as she is unable to care for herself independently. His ability to be adherent with his therapy is more dependent on factors beyond his control, and he should not be regarded as 'noncompliant' . 
Conclusions
A multi-component and targeted approach that is centred around CGA and builds on current infra structure and incorporates new research priorities, is urgently needed to meet the needs of a rapidly ageing population. Table 2 summarizes the most important gaps in knowledge and provides recommendations to help close the gaps in the next 10 years. 10 These mechanisms could help advance the research to close these gaps and improve care for older adults with cancer. Older patients, their families, and clinicians would ultimately benefit from research that improves the evidence base for onco logy care in older adults. Focusing efforts to improve geriatric oncology research would ultimately help clinicians to provide better quality of care to the most vulnerable of patients with cancer.
